Parkinson's Disease - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Parkinson's Disease - Pipeline Review, H1 2016

Parkinson's Disease - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Parkinson's Disease - Pipeline Review, H1 2016
Published Jun 28, 2016
833 pages — Published Jun 28, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Parkinson's Disease - Pipeline Review, H1 2016, provides an overview of the Parkinson's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Parkinson's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease
- The report reviews pipeline therapeutics for Parkinson's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Parkinson's Disease therapeutics and enlists all their major and minor projects
- The report assesses Parkinson's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Parkinson's Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by und

  
Source:
Document ID
GMDHC7961IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents244
  List of Tables396
  List of Figures451
Introduction461
  Global Markets Direct Report Coverage461
Parkinson's Disease Overview471
Therapeutics Development482
  Pipeline Products for Parkinson's Disease Overview481
  Pipeline Products for Parkinson's Disease Comparative Analysis491
Parkinson's Disease Therapeutics under Development by Companies5016
Parkinson's Disease Therapeutics under Investigation by Universities/Institutes663
Parkinson's Disease Pipeline Products Glance694
  Late Stage Products691
  Clinical Stage Products701
  Early Stage Products711
  Unknown Stage Products721
Parkinson's Disease Products under Development by Companies7318
Parkinson's Disease Products under Investigation by Universities/Institutes914
Parkinson's Disease Companies Involved in Therapeutics Development95179
  AC Immune SA951
  Acelot, Inc.961
  Acorda Therapeutics, Inc.971
  Addex Therapeutics Ltd981
  Advinus Therapeutics Ltd991
  Aeolus Pharmaceuticals, Inc.1001
  AFFiRiS AG1011
  Alexza Pharmaceuticals, Inc.1021
  Amabiotics SAS1031
  Amarantus Bioscience Holdings, Inc.1041
  American Gene Technologies International Inc.1051
  Anavex Life Sciences Corp.1061
  Angita B.V.1071
  Antoxis Limited1081
  APeT Holding BV1091
  ApoPharma Inc.1101
  Aposense Ltd.1111
  Araclon Biotech, S.L.1121
  ArmaGen Inc.1131
  Arrien Pharmaceuticals, LLC1141
  AstraZeneca Plc1151
  Berg LLC1161
  Bial - Portela &Ca, S.A.1171
  Bio-Modeling Systems SAS1181
  BioArctic Neuroscience AB1191
  Biogen, Inc.1201
  Bionature E.A. Ltd.1211
  Biopharm GmbH1221
  Biotie Therapies Corp.1231
  BrainStorm Cell Therapeutics Inc.1241
  CalAsia Pharmaceuticals, Inc.1251
  Calico LLC1261
  Cardax Pharmaceuticals, Inc.1271
  Carna Biosciences, Inc.1281
  Cell Cure Neurosciences, Ltd.1291
  Cellceutix Corporation1301
  CHA Bio &Diostech Co., Ltd.1311
  Chipscreen Biosciences Ltd1321
  Clera Inc.1331
  Clevexel Pharma SAS1341
  Contera Pharma ApS1351
  ContraVir Pharmaceuticals, Inc.1361
  Corium International, Inc.1371
  Corvus Pharmaceuticals, Inc.1381
  Curemark, LLC1391
  Cynapsus Therapeutics Inc.1401
  D-Pharm Ltd.1411
  Depomed, Inc.1421
  DermaXon, LLC1431
  Diffusion Pharmaceuticals Inc.1441
  Dizlin Medical Design AB1451
  Domain Therapeutics SA1461
  Edison Pharmaceuticals, Inc.1471
  Eli Lilly and Company1481
  Ensemble Therapeutics Corporation1491
  Euroscreen S.A.1501
  FPRT Bio Inc.1511
  Gene Solutions LLC1521
  Genecode AS1531
  Genentech, Inc.1541
  Genervon Biopharmaceuticals, LLC1551
  GenKyoTex S.A.1561
  Genosco1571
  Genzyme Corporation1581
  H. Lundbeck A/S1591
  Harbor Therapeutics, Inc.1601
  Heptares Therapeutics Limited1611
  Herantis Pharma Plc1621
  Hisamitsu Pharmaceutical Co., Inc.1631
  Huons Co., Ltd.1641
  Immune Design Corp.1651
  Immungenetics AG1661
  Impel NeuroPharma, Inc.1671
  Intec Pharma ltd.1681
  Integrative Research Laboratories Sweden AB1691
  InterMed Discovery GmbH1701
  International Stem Cell Corporation1711
  Intra-Cellular Therapies, Inc.1721
  Io Therapeutics, Inc.1731
  Iproteos S.L.1741
  Jeil Pharmaceutical Co., Ltd.1751
  Kainos Medicine, Inc.1761
  Khondrion BV1771
  KineMed, Inc.1781
  Kyowa Hakko Kirin Co., Ltd.1791
  Lead Discovery Center GmbH1801
  Ligand Pharmaceuticals, Inc.1811
  Living Cell Technologies Limited1821
  Longevity Biotech, Inc1831
  Luye Pharma Group Ltd.1841
  M et P Pharma AG1851
  M's Science Corporation1861
  M3 Biotechnology, Inc.1871
  MedGenesis Therapeutix Inc.1881
  Merck &Co., Inc.1891
  Merz Pharma GmbH &Co. KgaA1901
  Metabolic Solutions Development Company, LLC1911
  Minerva Neurosciences, Inc.1921
  Mission Therapeutics Limited1931
  Mitochon Pharmaceuticals, Inc.1941
  MitoDys Therapeutics Limited1951
  Motac Neuroscience Limited1961
  Netherlands Translational Research Center B.V.1971
  Neuralstem, Inc.1981
  Neuraltus Pharmaceuticals, Inc.1991
  Neuren Pharmaceuticals Limited2001
  NeuroDerm Ltd.2011
  Neurodyn Inc.2021
  NeuroNascent, Inc.2031
  Neuronax SAS2041
  NeurOp, Inc2051
  NeuroPhage Pharmaceuticals, Inc.2061
  Neuropore Therapies, Inc.2071
  New World Laboratories, Inc.2081
  Newron Pharmaceuticals S.p.A.2091
  nLife Therapeutics, S.L.2101
  NLS Pharma Group2111
  Novartis AG2121
  NsGene A/S2131
  Omeros Corporation2141
  Oncodesign SA2151
  Ono Pharmaceutical Co., Ltd.2161
  OPKO Health, Inc.2171
  Orion Oyj2181
  Oryzon Genomics S.A.2191
  Osmotica Pharmaceutical Corp.2201
  Oxford BioMedica Plc2211
  Peptron, Inc.2221
  Pfizer Inc.2231
  Pharma Two B Ltd2241
  PharmatrophiX, Inc.2251
  Pharmaxis Limited2261
  Pharmicell Co., Ltd.2271
  Pharnext SAS2281
  Prana Biotechnology Limited2291
  Prexton Therapeutics SA2301
  Primary Peptides, Inc.2311
  Promentis Pharmaceuticals, Inc.2321
  Promius Pharma, LLC2331
  Proteostasis Therapeutics, Inc.2341
  Prothena Corporation Plc2351
  QR Pharma, Inc.2361
  Raptor Pharmaceutical Corp.2371
  Reliance Life Sciences Pvt. Ltd.2381
  reMYND NV2391
  Retrotope, Inc2401
  RhinoCyte, Inc.2411
  Saje Pharma, LLC2421
  SanBio, Inc.2431
  Saneron CCEL Therapeutics, Inc.2441
  Saniona AB2451
  Sellas Inc.2461
  Serina Therapeutics, Inc.2471
  Shire Plc2481
  Sigma-Tau S.p.A.2491
  SignPath Pharma Inc2501
  Signum Biosciences, Inc.2511
  SK Biopharmaceuticals Co., Ltd.2521
  STATegics, Inc.2531
  Stelic Institute &Co., Inc.2541
  Synovo GmbH2551
  Synthonics, Inc.2561
  Takara Bio Inc.2571
  Takeda Pharmaceutical Company Limited2581
  TauRx Therapeutics Ltd.2591
  TechnoPhage SA2601
  Teikoku Pharma USA, Inc.2611
  Teva Pharmaceutical Industries Ltd.2621
  Titan Pharmaceuticals, Inc.2631
  Trevena, Inc.2641
  TyrNovo Ltd.2651
  UCB S.A.2661
  UniQure N.V.2671
  Vanton Research Laboratory, LLC2681
  Varinel, Inc.2691
  VistaGen Therapeutics , Inc.2701
  VivaCell Biotechnology Espana S.L.2711
  Voyager Therapeutics, Inc.2721
  Wellstat Therapeutics Corporation2731
Parkinson's Disease Therapeutics Assessment27434
  Assessment by Monotherapy Products2741
  Assessment by Combination Products2751
  Assessment by Target27618
  Assessment by Mechanism of Action29410
  Assessment by Route of Administration3042
  Assessment by Molecule Type3062
Drug Profiles308526
  (acamprosate calcium + baclofen) Drug Profile3082
  (carbidopa + levodopa prodrug) Drug Profile3101
  (carbidopa + levodopa) Drug Profile3113
  (carbidopa + levodopa) Drug Profile3141
  (carbidopa + levodopa) Drug Profile3151
  (carbidopa + levodopa) Drug Profile3161
  (carbidopa + levodopa) ER Drug Profile3172
  (carbidopa + levodopa) ER Drug Profile3191
  (carbidopa + levodopa) SR Drug Profile3201
  (pramipexole dihydrochloride + rasagiline mesylate) Drug Profile3212
  AAD-2004 Drug Profile3231
  ADA-409 Drug Profile3242
  ADX-88178 Drug Profile3262
  AEOL-11114 Drug Profile3281
  AEOL-11203 Drug Profile3291
  AEOL-11207 Drug Profile3302
  AG-0029 Drug Profile3321
  AGIL-AADC Drug Profile3331
  AGPD Drug Profile3341
  AGT-110 Drug Profile3351
  AGT-115 Drug Profile3361
  AGT-190 Drug Profile3371
  AK-7 Drug Profile3381
  alloswitch-1 Drug Profile3391
  AMA-101 Drug Profile3401
  AMRS-001 Drug Profile3419
  AMT-090 Drug Profile3501
  ANAVEX-141 Drug Profile3511
  ANAVEX-273 Drug Profile3528
  ANAVEX-371 Drug Profile3602
  Anle-138b Drug Profile3621
  Antibodies to Inhibit Amyloid Protein for CNS and Metabolic Disorders Drug Profile3631
  Antibody for Neurodegenerative Diseases and Diabetes Drug Profile3641
  Antisense Oligonucleotide to Inhibit GAD for Parkinson's Disease Drug Profile3651
  aplindore fumarate Drug Profile3661
  apomorphine hydrochloride Drug Profile3678
  apomorphine hydrochloride Drug Profile3751
  ATT-LD Drug Profile3761
  AV-101 Drug Profile3773
  AZ-009 Drug Profile3801
  AZD-1480 Drug Profile3812
  BAN-0805 Drug Profile3831
  BIIB-054 Drug Profile3841
  BNC-375 Drug Profile3851

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Parkinson's Disease - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Parkinson-s-Disease-Pipeline-Review-H1-2016-2088-16018>
  
APA:
Global Markets Direct - Market Research. (2016). Parkinson's Disease - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Parkinson-s-Disease-Pipeline-Review-H1-2016-2088-16018>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.